There are two recent breakthroughs in the treatment of follicular lymphoma: the optimization of first-line therapeutic options and the development of new drugs for relapsed refractory follicular lymphoma. 1. Optimization of first-line treatment options (1) Cure for early-stage patients: 95% CR rate and 96% overall remission rate after treatment with otuzumab combined with lenalidomide. (2) Delayed progression in late stage: with rituximab maintenance therapy, the overall survival rate of patients was significantly extended to 10.5 years. 2. Relapsed refractory follicular lymphoma: new anti-CD20 monoclonal antibody Mosun (Moussun), anti-CD19 CAR-T cell therapy – Tisagenlecleucel (no Chinese translation yet). If you are unfortunate enough to suffer from follicular lymphoma, you should go to the hospital for specific treatment and under the judgment of a professional doctor, and do not delay, as this may cause deterioration and development of the disease.